AstraZeneca PLC
AstraZeneca PLC Fundamental Analysis
AstraZeneca PLC (AZNCF) shows moderate financial fundamentals with a PE ratio of 30.75, profit margin of 17.53%, and ROE of 22.85%. The company generates $58.7B in annual revenue with strong year-over-year growth of 13.65%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 75.5/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze AZNCF's fundamental strength across five key dimensions:
Efficiency Score
WeakAZNCF struggles to generate sufficient returns from assets.
Valuation Score
WeakAZNCF trades at a premium to fair value.
Growth Score
ExcellentAZNCF delivers strong and consistent growth momentum.
Financial Health Score
ModerateAZNCF shows balanced financial health with some risks.
Profitability Score
ExcellentAZNCF achieves industry-leading margins.
Key Financial Metrics
Is AZNCF Expensive or Cheap?
P/E Ratio
AZNCF trades at 30.75 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, AZNCF's PEG of 3.52 indicates potential overvaluation.
Price to Book
The market values AstraZeneca PLC at 6.51 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 14.81 times EBITDA. This signals the market has high growth expectations.
How Well Does AZNCF Make Money?
Net Profit Margin
For every $100 in sales, AstraZeneca PLC keeps $17.53 as profit after all expenses.
Operating Margin
Core operations generate 23.40 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $22.85 in profit for every $100 of shareholder equity.
ROA
AstraZeneca PLC generates $9.03 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
AstraZeneca PLC generates strong operating cash flow of $14.73B, reflecting robust business health.
Free Cash Flow
AstraZeneca PLC generates strong free cash flow of $10.40B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $6.71 in free cash annually.
FCF Yield
AZNCF converts 3.29% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
30.75
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
3.52
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.51
vs 25 benchmark
P/S Ratio
Price to sales ratio
5.39
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.61
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.94
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.23
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.16
vs 25 benchmark
How AZNCF Stacks Against Its Sector Peers
| Metric | AZNCF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 30.75 | 29.28 | Neutral |
| ROE | 22.85% | 820.00% | Weak |
| Net Margin | 17.53% | -19731.00% (disorted) | Strong |
| Debt/Equity | 0.61 | 0.26 | Weak (High Leverage) |
| Current Ratio | 0.94 | 4.69 | Weak Liquidity |
| ROA | 9.03% | -17993.00% (disorted) | Weak |
AZNCF outperforms its industry in 1 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews AstraZeneca PLC's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
81.39%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
331.04%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
235.32%
Industry Style: Defensive, Growth, Innovation
High Growth